But beginning Tuesday, “Right of Entry” forms were made available, allowing residents to opt in or out of the clearance program. Details are available online at recovery.lacounty.gov/debris ...

Federal departments and agencies in the core public administration are required to make available to employees a confidential Employee Assistance Program (EAP). An EAP provides free short-term ...

Norovirus levels in hospitals in England are 80% higher than the same period last year, new figures show today as pressure on NHS services remains high. New data published today shows that 784 ...

Not only did AbbVie’s Skyrizi claim first place in the full-year ranking with nearly $377 million spent on 20 separate ads for the drug, according to iSpot.TV’s analysis, but, with two other ...

President Trump on Monday signed an executive order suspending any new U.S. foreign development assistance ... to continue the program in the same or in a modified form. . The measure encroaches ...

At the center, people can get help applying for federal assistance, speak to representatives from state and federal agencies, receive updates on their FEMA application for assistance and learn ...

Step 10. Take a print out of the filled application form and confirmation page for future reference. Candidates falling under the Scheduled Caste (SC), Special Central Assistance (SCA), and Scheduled ...

Read the instructions carefully and complete the application form. Step 5: Fill in the required information and pay the required category-wise application fees. Step 6: Submit the application form ...

Image credit: Skorzewiak / Shutterstock AbbVie executives say the company’s immunology drugs Skyrizi and Rinvoq are expanding their reach in the inflammatory bowel disease (IBD) as the market for ...

AbbVie closed out the year on a high note as its blockbuster biologic Skyrizi once again claimed ... all 10 counted the NFL as their top TV program, according to the month’s analysis.

AbbVie executives say the company’s immunology drugs Skyrizi and Rinvoq are expanding their reach in the inflammatory bowel disease (IBD) as the market for Humira biosimilars heats up.